the viewing window along with a small pair of shears (to cut the copper mesh which acts as the window's RF shield). The hospital engineers were immediately summoned and arrived within five minutes. After another 10 minutes the outer panel of the latching mechanism had been dismantled and the two 1cm diameter locking bolts freed. There had been no change in the patient's condition. Following the relatively simple repair of the mechanism, by replacing the errant screw, the scan was completed and the patient woken uneventfully. Since then a completely different latching mechanism has been installed but the debate about where the anaesthetist and the equipment need to be continues.
M A classic case of separation anxiety! Ed.
Guidewire-induced trauma after percutaneous tracheostomy Percutaneous dilatational tracheostomy 1 is now routine practice in the intensive care unit. Complications rates are reported to be comparable with forceps dilatation 2 . Comparisons with a conventional surgical approach have described a lower complication rate 3 but also a similar frequency of complications 4 . Bronchoscopy is advocated by some authors 5 to reduce the chance of tube misplacement and tracheal trauma. Damage to the trachea (usually by the dilators) is a well recognised complication 5 . We would like to report a case of guidewire-induced trauma to the bronchial tree, distal to the carina.
A 67-year-old woman was admitted to in the intensive care unit after a motor vehicle accident with chest and pelvic injuries. She was intubated for six days after which a percutaneous tracheostomy was inserted. We routinely use a Ciaglia dilator technique under bronchoscopic control. Insertion of the tracheostomy was performed according to the manufacturers' instructions 6 . Bronchoscopy via the tracheostomy was performed on completion of the procedure and fresh blood was present in the trachea which was oozing from a laceration at the origin of the right middle lobe bronchus. The injury was at 15 cm from tracheal stoma. The bleeding resolved spontaneously and bronchoscopy the next day showed a lesion at the origin of the right middle lobe bronchus. Subsequent tracheal aspirates were free from blood and progress chest radiographs showed no complications from the injury.
As far as we know this is the first report of bronchial injury from a guidewire complicating percutaneous tracheostomy. The plastic guiding catheter was kinked at the safety ridge which prevented the guidewire from sliding when a curve was applied during insertion. The impeded movement resulted in a kink in the guidewire 4 cm from its tip. As a result, a rigid section of the guidewire lacerated the subcarina at the junction of two bronchi. Ensuring that the wire is free to slide through the plastic guiding catheter, even under compression, would reduce the risk of airway trauma. Bronchoscopy did not prevent this complication but the presence of blood seen after insertion alerted us to the injury.
Blind nasal intubation and a telephone directory
A number of manoeuvres have been described to facilitate blind nasal tracheal intubation [1] [2] [3] [4] . The optimum position of the patient's head for blind nasal intubation was described by Magill 5 as "the position adopted when sniffing the morning air, the head on a single pillow, with slight extension of the atlantooccipital joint". However, our current standard issue pillows are too thin to suffice. We suggest that this position may be optimized further with the use of a phone directory. It is our routine practice to place an open copy of our 6 cm thick telephone directory under the patient's pillow prior to induction of anaesthesia. The advantage of this technique is that the thickness can be adjusted to the ideal position for the patient.
At the preoperative visit, the nares should be examined for patency by asking the patient to sniff with each naris occluded. If the right naris is used the head should be inclined 30° to the right, and vice versa. With the patient positioned as described, the tube is directed towards the inner third of the opposite clavicle. In most circumstances the tube will slip easily through the vocal cords at the first pass.
S. DAS M. CROSSE Southampton University Hospital, Southampton, U.K.
Ropivacaine overdose and systemic toxicity
Ropivacaine is a relatively new amide local anaesthetic, commercially available as a pure S-enantiomer, which is considered safer than bupivacaine on the basis of experimental and human reports indicating a lower systemic toxicity. We report a case of central nervous system (CNS) toxicity, without any cardiac rhythm and/or conduction disturbance, following an accidental overdose of ropivacaine injection intended for midhumeral brachial plexus block.
A 70-year-old, 49 kg, 153 cm ASA 2 woman presented for scheduled orthopaedic surgery of the left hand (interphalangeal arthrodesis of the first and second finger). She presented with non-symptomatic aortic insufficiency and stabilized arterial hypertension. There was no medical history of epilepsy. Clinical examination confirmed aortic insufficiency and also revealed limited extension of the cervical spine. Mallampatti score was 4, predicting difficult intubation if necessary. Blood samples (electrolytogram, haemogram, PRO-time, APTT) were within normal ranges. ECG showed minor left ventricular hypertrophy. Doppler echocardiography showed grade II-III aortic leak, normal size left ventricle and normal systolic function. The patient was given oral premedication with 0.5 mg alprazolam, 60 minutes before surgery. Full monitoring included pulse oximetry (SpO 2 ), non-invasive blood pressure and electrocardiogram (ECG). Blood pressure was 155/60 mmHg, heart rate 72 bpm and SpO 2 98%. Midazolam 2 mg was injected intravenously to enhance anxiolysis. Brachial plexus block was performed at the midhumeral level with a nerve stimulator, allowing individual location of each nerve. Ropivacaine 7.5 mg/ml was used. Nerve stimulation intensity and ropivacaine volumes were respectively; ulnar nerve; 0.7 mA, 7 ml: median nerve; 0.8 mA, 8 ml; musculocutaneous nerve: 0.6 mA, 7 ml; radial nerve: 0.6 mA, 8 ml. An additional 5 ml was injected for the brachial cutaneous nerves of the arm and forearm. Aspiration test was performed before each injection and remained negative for blood. The total dose of 35 ml (262.5 mg) was injected over eight to nine minutes, which subsequently appeared to be nearly twice the maximum dose for the patient's weight. Ten minutes after completion of the block, mental confusion occurred with disorientation, major anxiety, motor hyperactivity, garrulousness and shouting. The patient was no more able to understand and speak French despite usual fluency in this language and only spoke in the Vietnamese language. She was tachypneic and SpO 2 was 98% (room air). Blood pressure was 155/60 mmHg and ECG showed sinus tachycardia 130 bpm. Despite IV injection of midazolam 2 mg, agitation failed to stop. Two minutes later she lost consciousness and convulsed, exhibiting tonicclonic seizures. CNS toxicity was immediately evoked. Thiopentone 150 mg and succinylcholine 50 mg were injected IV, allowing tracheal intubation and ventilation. Blood samples were withdrawn immediately, that is 12 to 15 minutes after completion of the block (HO) and 15 minutes afterwards (HO+15). No arrhythmia, nor atrio-ventricular or intra-ventricular conduction abnormality was seen on the electrocardiogram. Convulsions stopped and she progressively recovered over 10 mintues. The decision was made to perform surgery and further sedation was achieved with propofol. Recovery was uneventful and there were no sequelae. The patient had no memory of the episode and she was given a full explanation of the incident. She was discharged home the following day. Analysis showed total plasma ropivacaine concentrations at HO and HO+15 min to be 5.22 µg/ml and 3.79 µg/ml respectively. This elderly woman, weighing 49 kg, received 262.5 mg of ropivacaine, which is a gross overdose considering recommendations of the manufacturer (200 mg in a 70 kg adult). It was responsible for severe CNS toxicity but no cardiac problem occurred, confirming once again the high cardiovascular safety profile of ropivacaine. Experimental data have given evidence of a lesser neuro-and cardio-toxicity than racemic bupivacaine 1,2 and, in the recent literature, ropivacaine has shown less cardiovascular depressant effects than bupivacaine. Several cases of convulsions have been reported following ropivacaine in brachial plexus blocks 3, 4 , sciatic nerve block 5 and also extradural anesthesia 6 . Ropivacaine 7.5 mg/ml was used in all these cases and injected doses were lower than in our observation (20 to 200 mg). A total dose of 5.35 mg/kg (262.5 mg) was injected in our patient, that is clearly exceeding the ranges of the experimental threshold for CNS toxic symptoms 1,2 . Ruetsch et al 5 recently reported severe cardiac dysrhythmia, but the authors insisted on the fact that successful treatment of these events was very easily and rapidly achieved, contrasting with bupivacaine-induced major cardiotoxic accidents which are always very difficult (or impossible) to resuscitate. This is undoubtedly a major advantage of ropivacaine. Therefore, because of the unpredictability of such an accident, we must always use the least toxic drug available 6 . We strongly believe that if relatively large doses of local anaesthetics are needed, then ropivacaine may be the agent of choice and will progressively replace bupivacaine in such indications. Systemic toxicity resulting from accidental injection remains a potential event, even in experienced hands and even when aspiration test is negative. Slow and fractionated injections, adequate monitoring and immediate availability of CPR drugs must then remain as intangible guidelines whatever the agent in use for regional anesthesia. No preventive technique has been shown infallible and vigilance must always prevail. This case also stressed that the dose in relation to the weight of the patient must be calculated when administering a large volume of local anaesthetics.
Awareness-An old approach
With discussion in the non-medical press concerning awareness, this is an opportune time to refresh anaesthetists' memories about the isolated forearm technique, as described by Tunstall 1 . This is a simple matter of inflating a tourniquet above systolic pressure on the arm opposite to that into which neuromuscular relaxants are being injected and leaving the cuff inflated until the relaxant drug is tissue-bound. With the earlier nondepolarizers such as d-tubocurarine, gallamine, alcuronium and pancuronium three minutes is required. Hence, even if the depolarizer suxamethonium was used (fixation <one minute) prior to a nondepolarizer, the cuff is released after five minutes. Thus, one forearm is not paralysed, allowing movement of wrist and fingers if the anaesthetic becomes too light for the procedure. Since I am no longer in anaesthetic practice, I do not know the fixation times of the newer relaxants.
I utilized this technique for over 20 years in patients whom I considered to be at risk from aware-ness, or in those who had suffered a previous episode of awareness. To my knowledge, no patient in those years had an episode of awareness. Two patients undergoing caesarean section did make slight hand movements early in their procedures, but they quickly ceased with rapid deepening of the anaesthetic. Neither had any recall of events. There were no complaints of circulatory problems in the limb.
In patients with a history of anaesthetic awareness, I did not guarantee that a similar episode would not happen, but I did reassure them that inability to communicate would not occur. The look of relief was worth the tiny effort it took to apply an additional sphygmomanometer.
Although future research may find a more scientific method of detecting awareness, the isolated forearm technique, with knowledge of fixation times, could be used now by every anaesthetist, the equipment being available in all operating theatres, and costing nothing.
A. G. CAMERON Melbourne, Victoria Reference 1. Tunstall ME. The reduction of amnesic wakefulness during caesarean section. Anaesthesia 1979; 34:316.
Xylocaine Heavy
Recently I found out indirectly that AstraZeneca had discontinued the supply of Xylocaine Heavy glass ampoules for spinal anaesthesia. Unfortunately, AstraZeneca did not notify anaesthetists nor did they consult anaesthetists prior to this change. I discovered the discontinuation in a letter sent to me by our Chief Pharmacist.
In the letter, AstraZeneca state that the decision to discontinue this product was taken due to the low usage of Xylocaine Heavy and the availability of other therapies that are proving to be the treatments of choice in this area. The low usage of this drug has presumably resulted from the considerable literature regarding the transient lumbar syndrome, which has been described following most drugs used for spinal anaesthesia but has the highest incidence with lignocaine. However studies have identified that high risk groups are those who are outpatients, placed in the lithotomy position or having knee surgery. It is my view that the drug is still a reasonable choice for lowrisk patients when short duration spinal anaesthesia is required.
Unfortunately, many anaesthetists are now utilizing other drugs such as procaine or prilocaine for short duration spinal anaesthesia but these drugs are not available in sterile ampoules. This may expose patients to a much more serious complication of spinal anaesthesia, that of meningitis.
I have discussed this issue with AstraZeneca and they appreciate that there is still a requirement for Xylocaine Heavy and that there is no sterile alternative at the present moment. AstraZeneca intend to reintroduce the drug but because of various issues, this will not occur for approximately six months from this date (August, 2000) .
M. DAVIES
Department of Anaesthesia, St Vincent's Hospital, Melbourne, Victoria
Apnoea with intrathecal morphine I wish to report a case of respiratory depression with apnoea in a 76-year-old woman (ASA2) with a history of untreated hypertension and moderate obesity, scheduled for a right total knee replacement. Because of the high degree of postoperative pain with this procedure, a single-shot spinal with a 25 gauge Whitacre needle, using bupivacaine 0.5% (isobaric) 2.2 ml and intrathecal morphine 0.4 mg (400 µg) was used. Midazolam 10 mg was used as premedicant one hour preoperatively. The only other agents used were midazolam 5 mg IV during the procedure, oxygen supplementation and tropisetron as routine antiemetic. This method of anaesthesia was chosen because it avoids epidural infusions for postoperative analgesia and associated use of low molecular weight heparins for deep vein thrombosis prophylaxis and epidural catheter management. The surgery was completed and the patient sent to Recovery, then to the high-dependency unit. No other analgesics were given.
Six hours after the administration of intrathecal morphine the patient became unresponsive and bradycardic with shallow inadequate respirations. This was treated with IPPV (bag and mask) and naloxone 0.2 mg IV to which the patient responded. There was also no change in the cardiovascular status other than bradycardia. The remainder of the postoperative course was uneventful with only oral analgesia being required. The sedation score was not assessed and was indeed not one of the parameters measured at this hospital. This has since been rectified.
Significant hypoxaemia can occur with normal respiratory rates, with sedation scores being a more important measure and indeed the respiratory rate in this patient was normal, around 15 to 16 breaths per minute before the adverse event. It is important that high-dependency unit staff is made aware on how to recognise the levels of sedation, which is the most important parameter. (Personal Communication, P. Macintyre). In a large series of 6,000 only a 3% incidence of respiratory depression was recorded, but they do not state how that was measured with doses given from 200 to 800 µg 1 . In another series they gave up to 1 mg of morphine with no significant respiratory depression but only 30 cases were studied 2 .
This case demonstrates that: a. Older patients require less morphine. In this age group the dose probably should not exceed 300 µg. b. Patients should be sent to the high-dependence unit for 24 hours to allow the frequent assessment of sedation scores as well as monitoring other parameters.
S. J. SCAMMELL Adelaide, South Australia
Vale supraclavicular brachial plexus block? In the past few months I have come across two anaesthetists, not long out of the training program (one doing a locum in our town and the other looking after me for a hand operation in Sydney) who told me that, although they had done lots of interscalene and axillary blocks, had never done a supraclavicular block.
It would appear from this that the technique is not taught, probably discouraged, and is in fact on the way out, like epidural anaesthesia 1 
. If this is the case what has happened?
Inadequate knowledge of the anatomy of the region may be a factor, but I have no doubt the main reason is concern about a pneumothorax. I believe it also stems from cases of overtreatment of the pneumothorax, i.e., admission, intensive care unit, largebore tube and underwater drain, multiple chest X-rays, etc. All this, together with a little residual pain at the drain site, is an invitation for Post Traumatic Stress syndrome.
Good technique does of course minimize this complication but in any case a "significant" pneumo-thorax should be a very rare event. When this does occur one only needs to withdraw the air with an intravenous-type catheter, syringe and three-way tap. I have not known one to reaccumulate.
It looks as thought the well known advantages of the supraclavicular approach, i.e., quickest onset, smallest dose, done with the arm in any position (trauma situation) and most of all reliably blocking all of the brachial plexus, have been passed over.
Instead of letting it pass into antiquity, perhaps we should hand it over to the Emergency Department physicians where there is a much greater application than in the operating theatres.
F 
Anticoagulants and local anaesthesia for eye surgery
Many patients presenting for eye surgery are elderly with complicated medical conditions. Increasingly they are taking some form of antiplatelet or anticoagulant therapy for cardiac, cerebrovascular or arthritic conditions. These range from aspirin and non-steroidal analgesics to warfarin. As a result of the potential risks of stopping these therapies, many eye surgeons now proceed with interventions from cataract to vitreoretinal repairs, either without altering the patients' medication regimens, or slightly reducing warfarin dosage to achieve a lowered therapeutic effect 1 . Concern has been expressed in the past over the placement of local anaesthetic eye blocks under conditions of anticoagulation, particularly retrobulbar blocks with their potential for catastrophic retrobulbar haemorrhage.
A retrospective review of 1000 consecutive patients' charts and theatre records at the Auckland Eye stand-alone day surgical unit was recently undertaken. Just over 30% (334) of patients presenting for intraocular surgery were on regular aspirin therapy. More than 5% (54) were on warfarin with INR levels, just prior to surgery, ranging from 1.6 to 3.6 with an average of 2.3. (Therapeutic range 2.0 to 4.0), (normal levels 0.8 to 1.2). It is not possible to comment on treatment with NSAIDs as documentation for these medications appeared incomplete. A number of patients presented on both aspirin and warfarin. The block of choice at the unit is the Subtenons block although some retrobulbar and peribulbar blocks are performed. Sub-tenons blocks were performed on the majority of patients on warfarin therapy.
There were no documented vision threatening complications of either surgery or anaesthetic blockade as a result of the anticoagulation or antiplatelet therapies. A prospective, long-term audit has been commenced to confirm these retrospective findings and compare the incidence of minor recognised complications of anticoagulation such as conjunctival haemorrhage, with untreated patients.
R. A. FRY

Department of Anaesthesia, Auckland Hospital, Auckland, New Zealand
Observed problems with the BLUELINE ULTRA Tracheostomy tube and inner cannula The recent introduction of the BLUELINE ULTRA Tracheostomy system (SIMS Portex Ltd, Hythe, Kent, U.K.) has attempted to address the clinical need for a well contoured tracheostomy tube with inner cannula. To date we have noted three problems with this system. 1: Frequent disconnection of some tracheostomy tubes from the 15 mm attachment of the breathing circuit angle connector. This appears to be due to the low friction material used in the 15 mm male hub- remove the inner cannula with the gloved hand, which may prove problematic if urgent removal of the inner cannula is required.
3: The appearance of cracks on the inner cannula- Figure 3 . These have all been along the long axis of the inner cannula to date. This problem has been associated with normal removal, cleaning and insertion and suggests the use of an excessively fragile thermoplastic material.
While none of our patients has in any way been adversely affected we feel it important to alert potential users of this system to the problems we have encountered.
J. E. GALLAGHER A. BANERJEE E. STACHOWSKI
Intensive Care Unit, Westmead Hospital, Sydney, N.S.W.
Observed problems with the BLUELINE ULTRA Tracheostomy tube and inner cannula-Reply
As manufacturers of the BLUELINE ULTRA Tracheostomy tube, we welcome an opportunity to make the following reply to the points raised by the authors.
With regard to the issue of disconnection from breathing circuits, all SIMS Portex Ltd. 15 mm connectors meet the requirements of the conical connector standard ISO 5356-1. However, we are aware that difficulties can occur when connectors at the extremes of the tolerances allowed by the standard are mated, or when connectors which meet the standards are mated to others which do not comply.
Since our introduction of the BLUELINE ULTRA tracheostomy range, we have been made aware of a small number of instances of low connector security. As a result, we have already modified the BLUE-LINE ULTRA 15 mm connectors, within the scope allowed by ISO 5356-1, to improve security of connection to other breathing system components commonly used in conjunction with our tracheostomy tube.
ISO 5356-1 requires an engagement force of 35N. In practice, such a force would rarely be applied when connecting a tracheostomy tube to a breathing system. The result of using a force lower than that specified in the standard is likely to be a reduced depth of insertion of the connector, but one which should still give an adequate level of security.
On the question of inner cannula and ring-pull robustness; as part of our normal design validation, the effect of repeated cleaning on the ring-pull and inner cannula was evaluated over a 30 day period and was found to be satisfactory. As a result of early market experience and in line with our policy of continuous improvement, we are presently examining the feasibility of making the inner cannula slightly more robust.
Whilst the very low level of adverse comment we have received suggests that the inner cannula is sufficiently durable to withstand most cleaning operations, more frequent replacement is advised where the need to remove tenacious secretions results in damage. 
